| New drug targets in Kaposi sarcoma. | |
| | |
MedLine Citation:
|
PMID: 21043836 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: Kaposi sarcoma (KS) occurs as a result of Kaposi sarcoma-associated herpesvirus (KSHV) infection, typically in the context of an immunodeficient state such as coinfection with HIV or transplantation. Systemic treatment of KS has traditionally involved one of several chemotherapeutic agents either in combination or as single agents, which typically provides reasonable response rates and short-term control. However, recurrence of KS is common and progression-free intervals are short. For these reasons, new therapies are being sought. AREAS COVERED IN THIS REVIEW: This review describes the contemporary pathobiology of KS targets, current limitations of standard treatment options, and examines the findings of completed and ongoing clinical trials of novel, molecularly targeted treatments for patients with KS. WHAT THE READER WILL GAIN: The reader will be presented with key clinicopathological characteristics and the pathogenesis of KS. Standard therapy for KS is reviewed including local, regional and systemic treatments. Molecular targets related to LANA-mediated and vGPCR-mediated signaling, angiogenesis, apoptosis and KSHV replication are discussed in detail. The reader will be provided with a compilation of agents, their mechanism of action, and results on various molecularly target agents in KS. TAKE HOME MESSAGE: With the elucidation of novel pathogenic mechanisms of KS including KSHV replication, restoration of immune competence and signal transduction pathways utilized by KSHV in the propagation of KS, rational therapeutic targets have been identified. |
| | |
Authors:
|
Ryan J Sullivan; Liron Pantanowitz |
Related Documents
:
|
9111476 - Effect of immunization with an inactivated gp120-depleted hiv-1 immunogen on beta-chemo... 9634076 - Dependence on host cell cycle for activation of human immunodeficiency virus type 1 gen... 20001886 - Genital and oral mucosal immune response against hiv-1 in exposed uninfected individuals. 11498306 - Reconstitution of cd4+ t lymphocytes in hiv-infected individuals following antiretrovir... 7495746 - Cross-linking of the tcr-cd3 complex with cd4, cd8 or lfa-1 induces an anti-apoptotic s... 12906096 - The suppressive effect of bifidobacteria on bacteroides vulgatus, a putative pathogenic... |
Publication Detail:
|
Type: Journal Article Date: 2010-11-02 |
Journal Detail:
|
Title: Expert opinion on therapeutic targets Volume: 14 ISSN: 1744-7631 ISO Abbreviation: Expert Opin. Ther. Targets Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101127833 Medline TA: Expert Opin Ther Targets Country: England |
Other Details:
|
Languages: eng Pagination: 1355-66 Citation Subset: IM |
Affiliation:
|
Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Hematology/Oncology, Boston, MA 02215, USA. rsulliva@bidmc.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is there a difference in outcomes between digital and fiberoptic flexible ureterorenoscopy procedure...
Next Document: Mathematical modeling of the transmission and control of foodborne pathogens and antimicrobial resis...